Tukysa Price in india | 9310090915

1. Tukysa for Metastatic HER2-Positive Breast Cancer Kinase inhibitor Tukysa is a cancer treatment. This powerful medication treats locally progressed or systemically distributed HER2-positive breast cancer. This indicates that the HER2 protein, produced by cancer cells and present on their surface, promotes tumor growth. Trastuzumab and capecitabine, two other medications, are used along with Tukysa. It is applied after at least two different HER2-positive cancer treatments have been administered and tested. The market has this effective medication available, and Tukysa priceis economical. Contact us for more details about the medication and ask for information about Tukysa Price in India It is offered in round 50 mg tablets and yellow, film-coated, oval 150 mg tablets containing tucatinib, the medication's active component. Only with a prescription can you buy this medication, and only a doctor with experience treating cancer should begin and oversee your treatment. Tukysa can have significant hepatotoxic side effects, and depending on how bad they are, the dose may be halted, lowered, or in rare circumstances, completely stopped. Therefore, the doctor must only choose the dose for better and enhanced effects with minimal toxicity. The drug is provided at Indian Pharma Network Tukysa is administered orally; the suggested dosage is 300 mg twice daily. Patients are given capecitabine and trastuzumab treatments on particular days of a 21-day cycle. As long as there is no advancement of cancer, it does not get worse, and the side effects are tolerable, treatment can continue. If specific adverse effects manifest, the doctor may advise a lower dose of Tukysa or temporarily or completely discontinue the medication. Tucatinib is the active ingredient of Tukysa. Tyrosine kinase inhibitors are a class of cancer medication. Tucatinib prevents the phosphorylation of HER2 and HER3, which in turn prevents the activation of MAPK and AKT signaling and the proliferation of cells. Binding to the HER2 protein on the cancer cells demonstrated anticancer effects in tumor cells expressing HER2. As a result, its action is inhibited. Because HER2 promotes cancer cell growth and division, inhibiting it aids in halting the growth of cancerous cells. They pass away as a result, which slows the spread of the cancer. This drug is available in the Indian market, and by taking the medication in the prescribed amount, as advised by the doctor, the desired result can be attained. Visit us or give us a call if you want to buy Tukysa tablets online for a reasonable price. Like any other cancer medication, Tukysa has certain negative side effects that come along with it. The most frequent adverse effects of Tukysa include nosebleeds, diarrhea, nausea, vomiting, stomatitis, arthralgia, palmar-plantar erythrodysesthesia, anemia, elevated levels of the liver enzymes ALT and AST as well as bilirubin in the blood, and weight loss. As many as one in ten Tukysa users may be impacted by this. Other more severe side effects of Tukysa that affect more than 1 in 20 users include diarrhea, elevated ALT and AST, hepatotoxicity, nausea, and vomiting, which can also be fatal Tukysa has the following drug interactions, which you should be aware of before taking the medication, despite the inexpensive cost of tucatinib. Ask your doctor for more information. • Strong CYP3A Inducers or Moderate CYP2C8 Inducers: It is best to refrain from using strong CYP3A Inducers or moderate CYP2C8 Inducers together. • Concomitant usage with strong CYP2C8 inhibitors should be avoided because it lowers the dosage of TUKYSA.

2. • Avoid providing your medication at the same time as CYP3A substrates. Because even small concentration changes can cause serious or even fatal toxicities. • P-gp Substrates: P-gp substrate dose should be decreased because even small concentration variations might have toxic effects that are lethal or life-threatening. The 50 mg and 150 mg Tukysa pills come in yellow, round, film-coated, and oval shapes. Each tablet has "TUC" debossed on one side, "50" on the other if it contains 50 mg, and "150" if it contains 150 mg. It is kept in a temperature-controlled room between 20°C and 25°C (68°F and 77°F). Dispense only in the original container to the patient. To keep it dry, it is kept in the original container. After each opening, the cap should be firmly restored. Desiccant doesn't need to be thrown away. Use within 3 months of opening. Throw away any unwanted pills three months after you've used them. To seek theprice of Tukysa in India, you can refer to Indian Pharma Networks, as it is among the most reliable dealers in India. Tucatinib is the active component of Tukysa while the list of inactive components in the tablet core also includes copovidone, crospovidone, sodium chloride, potassium chloride, sodium bicarbonate, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose. The yellow film coat used in Tukysa tablet coating comprises a non-irradiated yellow iron oxide, talc, polyvinyl alcohol, titanium dioxide, and macrogol/polyethylene glycol. It should be noted that patients with severe renal impairment are not advised to use Tukysa

3. in combination with capecitabine and trastuzumab since capecitabine is not advised for patients with severe renal impairment. This medication is being monitored further, which means that it is being watched over even more closely than other medications. It needs intensive care because it is therapeutically employed in breast neoplasms and neoplasm metastasis. With advanced or metastatic HER2-positive breast cancer, this medication has been shown to prolong the time patients could survive without their condition worsening. This medication is available with a prescription from a licensed vendor. Indian Pharma Network is one of India's authorized dealers and Tukysa suppliersthat has been providing real life-saving medications to patients worldwide for more than 8 years. • Diarrhea: It has been reported that severe diarrhea can lead to dehydration and acute renal injury, both of which can be fatal. Applying antidiarrheal medication as clinically necessary is advised. Depending on the severity, the dose for Tukysa may be paused, lowered, or permanently discontinued. • Hepatotoxicity: Tukysa has received reports of severe hepatotoxicity. Before starting Tucatinib, ALT, AST, and bilirubin, monitoring is carried out every 3 weeks during treatment and as clinically necessary. Depending on the severity, stop taking Tukysa altogether or reduce the dose. • Tukysa has the potential to actively damage fetuses. Patients are warned about possible fetal risk and encouraged to use reliable contraception. In the case of Pregnancy, Tucatinib can potentially harm a fetus if taken by pregnant women, as evidenced by several animal studies and the drug's mechanism of action. Therefore, it is advised that pregnant women avoid taking it, and they should always inform their healthcare provider if they are expecting it before beginning treatment. Tucatinib is not known to be present in milk during lactation. Since no studies support it, it is still unknown whether Tukysa metabolites are present in human milk or whether they impact the breastfed child or milk production. However, it is advised against breastfeeding due to the possibility of serious adverse reactions in breastfed children. Source - h#ps://tuksya.tumblr.com/post/720554902306291712/tukysa-for-metasta@c-her2- posi@ve-breast-cancer